Researchers have found a link between low testosterone levels and aggressive tumors, which could change how prostate cancer ...

The effects of the extent of lymph node dissection during radical prostatectomy on prostate cancer survival outcomes have been unclear, pending long-term follow-up data from randomized controlled ...

Former President Joe Biden was diagnosed with an “aggressive form” of prostate cancer that has a five-year survival rate of between 30% and 40%. The former president’s prostate cancer is characterized ...

Risks for prostate cancer metastasis or death appeared lower with GLP-1 RA use compared with use of other antidiabetic drugs. Patients with prostate cancer who take glucagon-like peptide-1 receptor ...

Prostate cancer is one of the most common malignancies affecting men globally, usually developing within the prostate gland. While in its early stages, the disease is often confined to the gland ...

(NYSE: PFE) today announced positive topline results from the Phase 3 TALAPRO-3 study of TALZENNA ® (talazoparib), an oral ...

Pfizer is eyeing an earlier use of its PARP inhibitor Talzenna after a positive phase 3 trial in metastatic hormone-sensitive ...

Germany has become a global leader in the treatment of metastatic prostate cancer, offering advanced, individualized care backed by cutting-edge research, innovative technologies, and a ...

The American Cancer Society estimates that more than 313,780 cases of prostate cancer will be diagnosed in the United States in 2025, resulting in approximately 35,770 deaths. Bone metastasis - a ...

Pfizer PFE reported positive top-line results from a late-stage study evaluating Talzenna (talazoparib), an oral PARP ...

Staging means finding out how far prostate cancer has spread in your body. Physicians group prostate cancers into stages I (1) through IV (4), with stage I being the least advanced and stage IV being ...